Endothelin receptor blockade ameliorates vascular fragility in endothelial cell-specific Fli-1-knockout mice by increasing Fli-1 DNA binding ability

Arthritis and Rheumatology

Volumn 67, Issue 5, 2015, Pages 1335-1344

  Akamata, Kaname ^a   Asano, Yoshihide ^a   Yamashita, Takashi ^a   Noda, Shinji ^a   Taniguchi, Takashi ^a   Takahashi, Takehiro ^a   Ichimura, Yohei ^a   Toyama, Tetsuo ^a   Trojanowska, Maria ^b   Sato, Shinichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ALPHA SMOOTH MUSCLE ACTIN; BOSENTAN; CDH5 PROTEIN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR; EVANS BLUE; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; GELATINASE B; MESSENGER RNA; PDGFB PROTEIN; PECAM1 PROTEIN; PROTEIN; PROTEIN KINASE C DELTA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FLI 1; UNCLASSIFIED DRUG; ACTIN; ALPHA-SMOOTH MUSCLE ACTIN, MOUSE; ENDOTHELIN RECEPTOR ANTAGONIST; FLI1 PROTEIN, MOUSE; SULFONAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CELLULAR DISTRIBUTION; CHROMATIN IMMUNOPRECIPITATION; DERMAL MICROVASCULAR ENDOTHELIAL CELL; DNA BINDING; ENZYME LOCALIZATION; FIBROBLAST; GENE INACTIVATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PERICYTE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTEMIC SCLEROSIS; VASCULAR FRAGILITY; ANIMAL; CAPILLARY PERMEABILITY; CELL CULTURE; CELL LINE; CYTOLOGY; ENDOTHELIUM CELL; GENE EXPRESSION; GENETICS; KNOCKOUT MOUSE; METABOLISM; MICROVASCULATURE; PHOSPHORYLATION; VASCULAR DISEASE;

ACTINS; ANIMALS; CAPILLARY PERMEABILITY; CELL LINE; CELLS, CULTURED; CHROMATIN IMMUNOPRECIPITATION; ENDOTHELIAL CELLS; ENDOTHELIN RECEPTOR ANTAGONISTS; ENDOTHELIN-1; GENE EXPRESSION; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MICE; MICE, KNOCKOUT; MICROVESSELS; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTEIN KINASE C-DELTA; PROTO-ONCOGENE PROTEIN C-FLI-1; PROTO-ONCOGENE PROTEINS C-ABL; RECEPTORS, ENDOTHELIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SCLERODERMA, SYSTEMIC; SULFONAMIDES; VASCULAR DISEASES;

EID: 84928622050     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39062     Document Type: Article

References (35)

1. Asano Y., Future treatments in systemic sclerosis. J Dermatol 2010; 37: 54-70.
2. Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, et al, for the RAPIDS-1 Study Group. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004; 50: 3985-93.
3. Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2011; 70: 32-8.
4. Guiducci S, Bellando Randone S, Bruni C, Carnesecchi G, Maresta A, Iannone F, et al. Bosentan fosters microvascular de-remodelling in systemic sclerosis. Clin Rheumatol 2012; 31: 1723-5.
5. Cutolo M, Zampogna G, Vremis L, Smith V, Pizzorni C, Sulli A., Longterm effects of endothelin receptor antagonism on microvascular damage evaluated by nailfold capillaroscopic analysis in systemic sclerosis. J Rheumatol 2013; 40: 40-5.
6. Hettema ME, Zhang D, Stienstra Y, Smit AJ, Bootsma H, Kallenberg CG., No effects of bosentan on microvasculature in patients with limited cutaneous systemic sclerosis. Clin Rheumatol 2009; 28: 825-33.
7. Shah P, Murray AK, Moore TL, Herrick AL., Effects of iloprost on microvascular structure assessed by nailfold videocapillaroscopy: a pilot study. J Rheumatol 2011; 38: 2079-80.
8. Asano Y, Czuwara J, Trojanowska M., Transforming growth factor-β regulates DNA binding activity of transcription factor Fli1 by p300/CREB-binding protein-associated factor-dependent acetylation. J Biol Chem 2007; 282: 34672-83.
9. Asano Y, Trojanowska M., Phosphorylation of Fli1 at threonine 312 by protein kinase C δ promotes its interaction with p300/CREB-binding protein-associated factor and subsequent acetylation in response to transforming growth factor β. Mol Cell Biol 2009; 29: 1882-94.
10. Asano Y, Trojanowska M., Fli1 represses transcription of the human α2(I) collagen gene by recruitment of the HDAC1/p300 complex. PLoS One 2013; 8: e74930.
11. Nakerakanti SS, Kapanadze B, Yamasaki M, Markiewicz M, Trojanowska M., Fli1 and Ets1 have distinct roles in connective tissue growth factor/CCN2 gene regulation and induction of the profibrotic gene program. J Biol Chem 2006; 281: 25259-69.
12. Noda S, Asano Y, Akamata K, Aozasa N, Taniguchi T, Takahashi T, et al. A possible contribution of altered cathepsin B expression to the development of skin sclerosis and vasculopathy in systemic sclerosis. PLoS One 2012; 7: e32272.
13. Noda S, Asano Y, Takahashi T, Akamata K, Aozasa N, Taniguchi T, et al. Decreased cathepsin V expression due to Fli1 deficiency contributes to the development of dermal fibrosis and proliferative vasculopathy in systemic sclerosis. Rheumatology (Oxford) 2013; 52: 790-9.
14. Wang Y, Fan PS, Kahaleh B., Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum 2006; 54: 2271-9.
15. Kubo M, Czuwara-Ladykowska J, Moussa O, Markiewicz M, Smith E, Silver RM, et al. Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol 2003; 163: 571-81.
16. Asano Y, Stawski L, Hant F, Highland K, Silver R, Szalai G, et al. Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy. Am J Pathol 2010; 176: 1983-98.
17. Akamata K, Asano Y, Aozasa N, Noda S, Taniguchi T, Takahashi T, et al. Bosentan reverses the pro-fibrotic phenotype of systemic sclerosis dermal fibroblasts via increasing DNA binding ability of transcription factor Fli1. Arthritis Res Ther 2014; 16: R86.
18. Ichimura Y, Asano Y, Akamata K, Takahashi T, Noda S, Taniguchi T, et al. Fli1 deficiency contributes to the suppression of endothelial CXCL5 expression in systemic sclerosis. Arch Dermatol Res 2014; 306: 331-8
19. Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K., Increased expression levels of integrin αVβ5 on scleroderma fibroblasts. Am J Pathol 2004; 164: 1275-92.
20. Ihn H, Tamaki K., Competition analysis of the human α2(I) collagen promoter using synthetic oligonucleotides. J Invest Dermatol 2000; 114: 1011-6.
21. Von Tell D, Armulik A, Betsholtz C., Pericytes and vascular stability. Exp Cell Res 2006; 312: 623-9.
22. Bujor AM, Asano Y, Haines P, Lafyatis R, Trojanowska M., The c-Abl tyrosine kinase controls protein kinase Cδ-induced Fli-1 phosphorylation in human dermal fibroblasts. Arthritis Rheum 2011; 63: 1729-37.
23. Distler JH, Gay S, Distler O., Angiogenesis and vasculogenesis in systemic sclerosis. Rheumatology (Oxford) 2006; 45 Suppl 3: iii26-7.
24. Rabquer BJ, Koch AE., Angiogenesis and vasculopathy in systemic sclerosis: evolving concepts. Curr Rheumatol Rep 2012; 14: 56-63.
25. Fleming JN, Nash RA, McLeod DO, Fiorentino DF, Shulman HM, Connolly MK, et al. Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? PLoS One 2008; 3: e1452.
26. Yamane K, Miyauchi T, Suzuki N, Yuhara T, Akama T, Suzuki H, et al. Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J Rheumatol 1992; 19: 1566-71.
27. Vancheeswaran R, Magoulas T, Efrat G, Wheeler-Jones C, Olsen I, Penny R, et al. Circulating endothelin-1 levels in systemic sclerosis subsets: a marker of fibrosis or vascular dysfunction? J Rheumatol 1994; 21: 1838-44.
28. Penn H, Quillinan N, Khan K, Chakravarty K, Ong VH, Burns A, et al. Targeting the endothelin axis in scleroderma renal crisis: rationale and feasibility. QJM 2013; 106: 839-48.
29. Asano Y, Bujor AM, Trojanowska M., The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis. J Dermatol Sci 2010; 59: 153-62.
30. Mayes MD, Trojanowska M., Genetic factors in systemic sclerosis. Arthritis Res Ther 2007; 9 Suppl 2: S5.
31. Frerix M, Stegbauer J, Dragun D, Kreuter A, Weiner SM., Ulnar artery occlusion is predictive of digital ulcers in SSc: a duplex sonography study. Rheumatology (Oxford) 2012; 51: 735-42.
32. Hasegawa M, Nagai Y, Tamura A, Ishikawa O., Arteriographic evaluation of vascular changes of the extremities in patients with systemic sclerosis. Br J Dermatol 2006; 155: 1159-64.
33. Ichimura Y, Asano Y, Hatano M, Tamaki Z, Takekoshi T, Kogure A, et al. Significant attenuation of macrovascular involvement by bosentan in a patient with diffuse cutaneous systemic sclerosis with multiple digital ulcers and gangrene. Mod Rheumatol 2011; 21: 548-52.
34. Abdelsaid M, Kaczmarek J, Coucha M, Ergul A., Dual endothelin receptor antagonism with bosentan reverses established vascular remodeling and dysfunctional angiogenesis in diabetic rats: relevance to glycemic control. Life Sci 2014; 118: 268-73.
35. Dreau D, Karaa A, Culberson C, Wyan H, McKillop IH, Clemens MG., Bosentan inhibits tumor vascularization and bone metastasis in an immunocompetent skin-fold chamber model of breast carcinoma cell metastasis. Clin Exp Metastasis 2006; 23: 41-53.